JCO Early Release, published online ahead of print Jun 18 2007
Journal of Clinical Oncology, 10.1200/JCO.2007.12.3430
Bone Density in Breast Cancer: When to Intervene?
Julie R. Gralow
University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA
Related Articles
- Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group
Michael F.X. Gnant, Brigitte Mlineritsch, Gero Luschin-Ebengreuth, Stephan Grampp, Helmut Kaessmann, Marianne Schmid, Christian Menzel, Jutta Claudia Piswanger-Soelkner, Arik Galid, Martina Mittlboeck, Hubert Hausmaninger, and Raimund Jakesz
JCO 2007 25: 820-828
[Abstract]
[Full Text]
- Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer
Adam Brufsky, W. Graydon Harker, J. Thaddeus Beck, Robert Carroll, Elizabeth Tan-Chiu, Christopher Seidler, John Hohneker, Leo Lacerna, Stephanie Petrone, and Edith A. Perez
JCO 2007 25: 829-836
[Abstract]
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
S. L. Greenspan, A. Brufsky, B. C. Lembersky, R. Bhattacharya, K. T. Vujevich, S. Perera, S. M. Sereika, and V. G. Vogel
Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
J. Clin. Oncol.,
June 1, 2008;
26(16):
2644 - 2652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
